Business Atlas

How Enterprise Is Built
Sign In
Text size
100%
Theme
Companies and Brands

EssilorLuxottica

Health Care

EssilorLuxottica is a Franco Italian vertically integrated multinational holding company headquartered in both Paris and Milan, formed on 1 October 2018 through the merger of the French company Essilor and the Italian company Luxottica. It designs, produces and markets ophthalmic lenses, equipment and instruments, and prescription glasses and sunglasses, and because Essilor and Luxottica had respectively been the leading manufacturers of ophthalmic lenses and eyeglasses in the world, the merger effectively created a monopoly in those combined markets. Its brands include Ray-Ban, Oakley and Persol, sold through a retail network of more than 17,000 stores.

Facts
Company Type
Public 1
Founded Year
2018 2
Size Band
100,000 or More 1
Listing
Other Exchange 1
Status
Active 3
Company Type
Company Type (category)
Public 1
In the Other Atlases

Located In

Also in Geography Atlas: where this subject is located.

Sources
1. EssilorLuxottica (Wikipedia)
  • Infobox: num_employees
    203,791
  • Lead section, listing
    The company is listed on the Euronext Paris stock exchange under the trading symbol "EL" and is part of the CAC 40 share index, which includes the 40 largest capitalized companies traded on the Paris Stock Exchange, and the Euro Stoxx 50, which includes the 50 largest companies in the Eurozone.
  • Lead section
    Essilor and Luxottica were respectively the world's leading manufacturers of ophthalmic lenses and of eyeglasses; upon the merger, EssilorLuxottica thus became a monopoly.
View the Source
2. Wikipedia: EssilorLuxottica
Wikipedia
  • Founded Year: 2018
3. StockAnalysis.com: EssilorLuxottica Société anonyme (EPA:EL) company profile
StockAnalysis.comProfile: quote header
Quote, Profile: quote header
EssilorLuxottica Société anonyme (EPA:EL) France · Delayed Price · Currency is EUR
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.